Trial reportTranslational stroke research2025
Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial.
Trial report in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct 2
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects and mechanisms of transcutaneous auricular vagus nerve stimulation on post-stroke cognitive impairment in animal studies: a systematic review and meta-analysis.Frontiers in neuroscience · 2026Pooled it
- Effects of Transcutaneous Vagus Nerve Stimulation on Cerebral Perfusion and Cognitive Function Under Simulated High-Altitude Hypobaric Hypoxia.Brain and behavior · 2026Trial
- Neurofilament light chain dynamics following ischemic stroke and their modulation by transauricular vagus nerve stimulation.Scientific reports · 2026Trial
- tVNS and obesity-related inflammation: a prospective sham-controlled randomized crossover study protocol.BMC psychology · 2026Article
- Transcutaneous vagus nerve stimulation in breast cancer: a neuroimmune model to improve quality of life.Frontiers in oncology · 2026Article
- Transcutaneous auricular vagus nerve stimulation: mechanisms, applications, and research progress.Frontiers in neuroscience · 2026Review
- Transcutaneous Auricular Vagus Nerve Stimulation for Treating Emotional Dysregulation and Inflammation in Common Neuropsychiatric Disorders.Brain sciences · 2025Review
- Cholinergic reflex control of inflammation: mechanistic and translational advances in transcutaneous auricular vagus nerve stimulation across rheumatic, metabolic, and postoperative disorders.Frontiers in immunology · 2025Review
- Efficacy of transcutaneous auricular vagus nerve stimulation in treating patients with post-stroke motor disorders: a prospective study.Frontiers in neurologyArticle
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Inflammation exacerbates brain injury following acute ischemic stroke (AIS). Transcutaneous auricular vagus nerve stimulation (taVNS) reduces systemic inflammation, but its efficacy in AIS remains unexplored. We examined the safety and anti-inflammatory effect of taVNS in AIS patients. Prospective Randomized Open-label blinded endpoint design, sham-controlled trial. Anterior circulation large vessel occlusion (LVO) AIS patients were assigned to twice-daily taVNS or sham stimulation for five days or until discharge. Inclusion criteria: age≥18 years, NIHSS≥6, anterior circulation LVO, and enrollment within 36-hours of last known normal (LKN). Primary endpoints were changes in inflammatory biomarkers (interleukins (IL)-1β, 6, 10, 17α, and tumor necrosis factor alpha (TNFα) on Days 0, 1, 3, 5, and 7). TaVNS safety endpoints included bradycardia, hypotension, infection, and death. Thirty-five patients (17 taVNS, 18 sham) were enrolled and taVNS/sham treatment started a mean of 0.99 days (SD 0.26 days) from LKN. Mean stimulations received were 8.24 (SD 2.77) and 7.33 (SD 3.20), for treatment vs. sham respectively. The rate of protocol adherence was 77%. TaVNS treatment significantly changed IL-6 levels compared to sham treatment (overall p=0.0001). Although overall trajectories of other cytokines did not significantly differ between groups, a post-hoc analysis found significant differences on day 3 cytokine levels between groups for: IL-1β (p=0.024), IL-6 (p=0.045), and IL-17α (p=0.044). No significant difference between treatment groups in safety endpoints were found. taVNS safely reduced post-AIS inflammation in anterior circulation LVO patients. These findings warrant further investigation in larger clinical trials.ClinicalTrials.gov ID: NCT05390580, https://clinicaltrials.gov/study/NCT05390580 -Study started/registered: September 26, 2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.